Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

Macular Diseases

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Clin Exp Ophthalmol.

Spooner K, Fraser-Bell S, Hong T, Chang A

doi: 10.1111/ceo.13636.

Macular Diseases

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies

J Clin Med.

Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, Toro MD

doi: 10.3390/jcm9051522.

Macular Diseases

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration

BMC Ophthalmol.

Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R

doi: 10.1186/s12886-018-0960-6.

Further Publications

Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks

Eur J Ophthalmol.

Sekfali R, Mimoun G, Cohen SY, Querques G, Bandello F, Sacconi R, Souied EH, Capuano V

doi: 10.1177/

Macular Diseases

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

Ophthalmology.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd

doi: 10.1016/j.ophtha.2020.01.029.

Macular Diseases

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

Ophthalmology.

Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D

doi: 10.1016/j.ophtha.2019.10.006.

COMMENTED

Macular Diseases

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

doi: 10.1016/j.ophtha.2020.03.021.

Macular Diseases

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab

JAMA Ophthalmol.

Parikh R, Avery RL, Saroj N, Thompson D, Freund KB

doi: 10.1001/jamaophthalmol.2019.1947.

Macular Diseases

Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial

JAMA Ophthalmol.

Scoles D, Ying GS, Pan W, Hua P, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Martin DF, Maguire MG, Comparison of AMD Treatments Trials Research Group.

doi: 10.1001/jamaophthalmol.2019.5831.

Related content

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies

The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration

Switching from ranibizumab to aflibercept in choroidal neovascularization secondary to angioid streaks

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab

Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial